These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 34885115)

  • 1. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
    Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
    Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
    Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
    Li S; Lin X; Sun S; Li S; Zhou C
    Anticancer Drugs; 2022 Oct; 33(9):963-965. PubMed ID: 36136993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting
    Aboubakar Nana F; Ocak S
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.
    Yu D; Zhao W; Vallega KA; Sun SY
    Lung Cancer (Auckl); 2021; 12():1-10. PubMed ID: 33574724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44.
    Wu SG; Chang TH; Tsai MF; Liu YN; Huang YL; Hsu CL; Jheng HN; Shih JY
    Mol Ther Nucleic Acids; 2024 Mar; 35(1):102091. PubMed ID: 38130372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer.
    Li X; Chen C; Wang Z; Liu J; Sun W; Shen K; Lv Y; Zhu S; Zhan P; Lv T; Song Y
    Cancer Cell Int; 2021 Aug; 21(1):428. PubMed ID: 34391435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DUSP1 Promotes Osimertinib Drug-Tolerant Persistence by Inhibiting MAPK/ERK Signaling in Non-small Cell Lung Cancer.
    He W; Liu P; Lei Q; Xu J; Liu L
    Mol Biotechnol; 2024 Mar; ():. PubMed ID: 38551790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.
    Huang G; Liu X; Jiang T; Cao Y; Sang M; Song X; Zhou B; Qu H; Cai H; Xing D; Mao Y; Lin G; Liu X; Zheng X
    Am J Cancer Res; 2023; 13(9):4145-4162. PubMed ID: 37818074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer.
    Kaźmierczak D; Eide IJZ; Gencheva R; Lai Y; Lewensohn R; Tsakonas G; Grundberg O; de Petris L; McGowan M; Brustugun OT; Ekman S; Hydbring P
    Transl Lung Cancer Res; 2022 May; 11(5):722-734. PubMed ID: 35693293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.
    Ninomiya K; Ohashi K; Makimoto G; Tomida S; Higo H; Kayatani H; Ninomiya T; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
    Sci Rep; 2018 Jan; 8(1):1955. PubMed ID: 29386539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis.
    Zhao Y; Jia Y; Wang J; Chen X; Han J; Zhen S; Yin S; Lv W; Yu F; Wang J; Xu F; Zhao X; Liu L
    Mol Cancer; 2024 Mar; 23(1):47. PubMed ID: 38459511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA LOC554202 promotes acquired gefitinib resistance in non-small cell lung cancer through upregulating miR-31 expression.
    He J; Jin S; Zhang W; Wu D; Li J; Xu J; Gao W
    J Cancer; 2019; 10(24):6003-6013. PubMed ID: 31762810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer.
    Takatsu F; Suzawa K; Tomida S; Thu YM; Sakaguchi M; Toji T; Ohki M; Tsudaka S; Date K; Matsuda N; Iwata K; Zhu Y; Nakata K; Shien K; Yamamoto H; Nakayama A; Okazaki M; Sugimoto S; Toyooka S
    J Mol Med (Berl); 2023 Dec; 101(12):1603-1614. PubMed ID: 37831111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.
    Xia L; Yang F; Wu X; Li S; Kan C; Zheng H; Wang S
    Cancer Cell Int; 2021 Jul; 21(1):337. PubMed ID: 34217295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.
    Liu Y; Xiong ZC; Sun X; Sun L; Zhang SL; Ma JT; Han CB
    Transl Cancer Res; 2019 Sep; 8(5):2151-2163. PubMed ID: 35116965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.